Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders

Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders

Adolescent healthcare demands a sophisticated understanding of evolving legal competence, confidential risk mitigation, reproductive rights, and life-threatening behavioural emergencies. Paediatricians frequently navigate complex ethical dilemmas where parental desires conflict with adolescent autonomy, necessitating an objective, evidence-based approach grounded in European clinical standards.

---

Legal and Ethical Frameworks in European Adolescent Healthcare

The legal landscape governing adolescent healthcare balances parental rights with the young person's evolving developmental capacity. While paediatric care historically relied on parental consent, modern medical ethics recognizes that capacity is decision-specific rather than strictly determined by chronological age.

Consent versus Assent

• Paediatric Assent: The affirmative agreement of a child or young person who lacks full legal competence to participate in healthcare interventions. Obtaining assent respects developing autonomy by providing age-appropriate information, answering questions, and soliciting the patient's agreement, even when parental permission is legally definitive.
• Independent Legal Consent: The autonomous, legally binding authorization for medical treatment provided by a young person who possesses sufficient cognitive capacity and emotional maturity to fully appreciate the proposed intervention.

Evolving Capacity: Fraser Guidelines and Gillick Competence

In England and Wales, the 1985 Gillick judgment permits an under-16 with sufficient maturity and understanding to consent to the particular treatment. Other European jurisdictions use their own legal rules; assess the young person’s understanding and apply the law governing the consultation.

For confidential contraceptive advice and treatment for an under-16 in the UK, the Fraser guidelines require the following five criteria. They are not a general consent test for every sensitive treatment:

+--------------------------------------------------------------------------+
|                       THE FIVE FRASER GUIDELINES CRITERIA                |
|                                                                          |
|   1. The young person possesses sufficient maturity to understand the     |
|      nature, purpose, risks, and implications of the proposed treatment.  |
|   2. The clinician cannot persuade the young person to inform their      |
|      parents, nor will the adolescent permit the clinician to do so.     |
|   3. The young person is very likely to begin or continue sexual activity |
|      with or without contraceptive treatment.                   |
|   4. The physical or mental health (or both) of the young person is       |
|      likely to suffer unless they receive contraceptive advice or care.   |
|   5. The best interests of the young person require the provision of      |
|      treatment/advice without parental involvement.                      |
+--------------------------------------------------------------------------+

European countries differ in their legal ages, capacity tests and requirements for parental authorisation or joint consent. Do not infer a uniform right to independent medical consent from a country’s age threshold alone. Apply the national rules for the particular intervention while involving the adolescent in the decision.

Confidentiality and Lawful Disclosure

Confidentiality is an indispensable prerequisite for adolescent healthcare. Empirical data demonstrates that when adolescents fear parental disclosure, up to 50% avoid seeking care for sexually transmitted infections, contraception, mental health crises, or substance use.

Applying the Limits of Confidentiality

Confidentiality is the starting point, but its exceptions depend on national law and the clinical circumstances. UK GMC guidance permits disclosure without consent when required by law or a court, justified by overriding public interest, or necessary in the best interests of a young person who cannot decide about disclosure.

Serious-harm concerns include suicidal behaviour, dangerous substance use or driving, threats to others, and abuse, neglect or exploitation. They need a documented, proportionate assessment; risk need not fit a fixed three-event list. Seek safeguarding or senior advice when uncertain.

Share only relevant information with appropriate people. Normally tell the adolescent what will be disclosed and why, and involve them in the discussion. Do not give advance warning when it would increase danger, undermine safeguarding or otherwise defeat the disclosure's purpose. Parental disclosure is not automatic whenever a health risk is identified.

Adolescent Risk-Taking and Substance Misuse

Adolescent substance experimentation reflects the interplay between biological reward-seeking and social environments. ESPAD 2024 surveys of European students aged 15–16 show long-term declines in cigarette smoking, alcohol use, binge drinking and cannabis use, alongside increasing e-cigarette use and non-medical pharmaceutical use.

The CRAFFT Screening Questionnaire (Version 2.1)

The CRAFFT questionnaire is the most widely validated behavioural health screening tool for children and adolescents aged 12 to 21 years. First ask the Part A past-year frequency questions. If all answers are zero, ask CAR only; if any use is reported, ask all six CRAFFT items. Each positive item scores one point:

+--------------------------------------------------------------------------+
|                       CRAFFT SCORING & CLINICAL ACTION                   |
|                                                                          |
|   No past-year use AND score 0: LOW RISK                               |
|   --> Reinforce healthy choices; discuss substance/driving safety.     |
|                                                                        |
|   No use but CAR positive, OR any use with score 0–1: MEDIUM RISK      |
|   --> Brief advice, safety planning and follow-up as appropriate.      |
|                                                                        |
|   Past-year use AND score >=2: HIGH RISK                               |
|   --> Brief intervention, further assessment and follow-up;            |
|       consider referral according to severity and treatment needs.     |
+--------------------------------------------------------------------------+

Brief Motivational Interviewing (MI)

Confrontational, punitive lecturing provokes defensiveness and paradoxically reinforces substance use. Clinicians must utilize Motivational Interviewing (MI) techniques grounded in the OARS framework:

• O — Open-Ended Questions: “What are some of the things you enjoy about vaping with friends, and what are some things you dislike?”
• A — Affirmations: “I really appreciate your honesty in sharing this with me today—it takes courage to talk openly about alcohol use.”
• R — Reflective Listening: “So, smoking cannabis helps you unwind when school feels overwhelming, but you're finding it harder to wake up for morning classes.”
• S — Summarizing: Integrating the adolescent's stated personal values with their substance use to elicit internal dissonance and stimulate 'change talk'.

---

Adolescent Sexual and Reproductive Healthcare

Adolescent reproductive healthcare must be accessible, confidential, and technically rigorous. Clinicians must provide comprehensive sexuality education, promote dual-protection strategies, conduct proactive STI screening, and recommend high-efficacy contraception.

Sexually Transmitted Infection (STI) Surveillance

Young people carry a substantial STI burden in Europe; reported chlamydia rates are highest in young adults, while gonorrhoea age patterns vary by sex and exposure group. Anatomical vulnerabilities, such as cervical ectopy (presence of delicate, single-cell columnar epithelium on the ectocervix), increase biological susceptibility to pathogens.

• Chlamydia trachomatis and Neisseria gonorrhoeae: Chlamydia is often asymptomatic. Gonorrhoea is usually symptomatic in the male urethra but often silent at cervical, rectal or pharyngeal sites. First-catch morning urine nucleic acid amplification testing (NAAT) in males or self-collected vulvovaginal swabs in females offer non-invasive, highly sensitive screening.
• Human Papillomavirus (HPV): Vaccinate before HPV exposure using the current national programme. The 9-valent vaccine covers types 6, 11, 16, 18, 31, 33, 45, 52 and 58, preventing associated cancers and anogenital warts. Routine schedules may use one or two doses; for example, England uses one dose at 12–13 years, with three doses for immunosuppressed or HIV-positive recipients.
• Dual Protection: Clinicians must emphasize that while hormonal and intrauterine contraceptives prevent pregnancy, they provide zero protection against STIs. Barrier condoms must be utilized concurrently for all penetrative sexual encounters.

Adolescent Contraception Hierarchy

Modern guidelines from the World Health Organization (WHO), European Society of Contraception (ESC), and American Academy of Pediatrics (AAP) designate Long-Acting Reversible Contraception (LARC) as the first-line choice for adolescents due to near-zero failure rates that are completely independent of daily adherence.

Emergency Contraception (EC)

Emergency contraception must be provided rapidly without barriers following unprotected sexual intercourse, condom breakage, or sexual assault.

+--------------------------------------------------------------------------+
|               EMERGENCY CONTRACEPTION TIMELINE & EFFICACY                |
|                                                                          |
|   [ 0 to 72 Hours Post-Coitus ]                                          |
|   --> Oral Levonorgestrel 1.5 mg single dose                             |
|       - Delays LH surge; efficacy decreases over time                    |
|       - Reduced efficacy in patients weighing >70 kg (BMI >25 kg/m2)     |
|                                                                          |
|   [ 0 to 120 Hours (5 Days) Post-Coitus ]                                |
|   --> Oral Ulipristal Acetate (UPA) 30 mg single dose                    |
|       - Selective Progesterone Receptor Modulator                        |
|       - Delays follicular rupture even after LH has begun to rise                  |
|       - SUPERIOR efficacy to levonorgestrel; consistent across 120 hrs   |
|                                                                          |
|   --> Copper Intrauterine Device (Cu-IUD)                                |
|       - Inserted up to 5 days (120 hrs) post-coitus                      |
|       - MOST EFFECTIVE EC (>99.9% effective); immediate long-term method |
+--------------------------------------------------------------------------+

---

Adolescent Eating Disorders: Clinical Phenotypes and Red Flags

Eating disorders are life-threatening psychiatric conditions with profound somatic consequences, demonstrating peak onset during early-to-middle adolescence.

Diagnostic Spectra (DSM-5 & ICD-11)

1. Anorexia Nervosa (AN): Persistent restriction of energy intake leading to significantly low body weight; intense fear of gaining weight or becoming fat; distorted perception of body weight/shape. Categorized into:
   • Restricting Type: Weight loss accomplished primarily through dieting, fasting, and excessive exercise without binge/purging.
   • Binge-Eating / Purging Type: Recurrent binge eating or purging (self-induced vomiting or misuse of laxatives, diuretics or enemas); both need not occur together.
2. Bulimia Nervosa (BN): Recurrent episodes of binge eating accompanied by a sense of lack of control, followed by inappropriate compensatory behaviors (purging, fasting, over-exercising) to prevent weight gain. Weight is often within the normal range; interpret adolescent BMI for age and sex rather than using adult cutoffs. Somatic markers include bilateral parotid sialadenosis, dental perimylolysis (enamel erosion from gastric acid), Russell sign (calluses on dorsal metacarpophalangeal joints from induced gagging), and hypokalaemic hypochloraemic metabolic alkalosis.
3. Avoidant/Restrictive Food Intake Disorder (ARFID): Clinically significant failure to meet nutritional needs leading to weight loss, nutritional deficiency, or oral supplement dependency. Crucially, ARFID lacks body image distortion or fear of fatness; intake restriction is driven by sensory sensitivity (texture, smell), lack of interest in eating, or fear of aversive consequences (phobia of choking, dysphagia, or vomiting).

Clinical Examination Red Flags and Medical Admission Criteria

Paediatricians must not rely on subjective patient reporting; eating disorders carry high biological denial. Admission considers physiological instability, nutritional trajectory, mental health, outpatient resources and family support. SAHM 2022 lists the following factors supporting hospitalisation; NICE/MEED require comprehensive, age-appropriate assessment rather than one universal cutoff or BMI alone.

---

Refeeding Syndrome: Pathophysiology and Prevention

Refeeding syndrome is a potentially fatal metabolic complication occurring when carbohydrate nutrition is rapidly reintroduced into a chronically malnourished, starved patient.

+--------------------------------------------------------------------------+
|                 PATHOPHYSIOLOGY OF REFEEDING SYNDROME                    |
|                                                                          |
|   Chronic Starvation / Severe Caloric Restriction                        |
|   - Catabolism: Lipolysis and protein breakdown provide substrate        |
|   - Whole-body depletion of Phosphate, Potassium, Magnesium              |
|   - Basal insulin levels severely suppressed; glucagon elevated          |
|         │                                                                |
|         ▼                                                                |
|   Rapid Re-introduction of Carbohydrates / High-Calorie Feeding          |
|         │                                                                |
|         ▼                                                                |
|   Surge in Pancreatic Insulin Secretion                                  |
|         │                                                                |
|         ▼                                                                |
|   Massive Cellular Uptake of Glucose, Phosphate (PO4), K+, Mg2+          |
|   - Phosphate consumed to synthesize ATP and 2,3-BPG                     |
|         │                                                                |
|         ▼                                                                |
|   FULMINANT BIOCHEMICAL DEFICITS IN EXTRACELLULAR COMPARTMENT:           |
|   1. Hypophosphataemia: Loss of ATP --> Diaphragmatic weakness,          |
|      impaired myocardial contractility, acute rhabdomyolysis, seizures   |
|   2. Hypokalaemia: Cardiac arrhythmias, cardiac arrest, paralytic ileus  |
|   3. Hypomagnesaemia: Refractory hypokalaemia, tetany, torsades         |
|   4. Fluid Retention: Sodium and water retention --> Acute pulmonary     |
|      edema and congestive heart failure                                  |
+--------------------------------------------------------------------------+

Evidence-Based Prevention and Management

1. Pre-Feeding Baseline Assessment: Measure baseline serum phosphate, potassium, magnesium, calcium, renal function, liver enzymes, and an 12-lead ECG prior to starting nutritional rehabilitation.
2. Thiamine Supplementation: Starvation depletes thiamine (vitamin $B_1$), a critical cofactor in pyruvate dehydrogenase and carbohydrate metabolism. Always administer oral or IV thiamine ($100\text{--}200\text{ mg}$ daily) before initiating caloric reintroduction to prevent acute Wernicke encephalopathy and lactic acidosis.
3. Risk-Calibrated Refeeding: Use a specialist protocol that avoids both refeeding syndrome and underfeeding. MEED 2022 (updated 2025) supports adolescent starts of 1400–2000 kcal/day, increasing by at least 200 kcal/day, except at highest risk. Its high-risk pathway starts at 20 kcal/kg/day, increasing by 5 kcal/kg every 2 days with close monitoring. Choose the pathway from clinical risk, recent intake and malnutrition severity; NICE does not prescribe a universal 1200–1400 kcal start.
4. Electrolyte Monitoring and Replacement: Monitor phosphate, potassium and magnesium frequently during early refeeding; high-risk patients may need 12–24-hourly tests initially. Use age-appropriate ranges and the specialist protocol for preventive supplementation or correction. Oral/enteral phosphate is preferred for mild/moderate asymptomatic deficiency; use monitored IV replacement for severe or symptomatic hypophosphataemia or when enteral treatment is unsuitable. Correct deficiencies alongside nutritional rehabilitation.
5. Fluid Restriction: Avoid aggressive IV fluid boluses. Starved hearts possess atrophic left ventricular mass; excessive sodium and fluid loading rapidly triggers acute congestive heart failure and pulmonary edema.